New Antibiotic Discovered Against Drug-Resistant Pathogens In Microbes From Italian Soil By Lester Mondragon | Jun 25, 2017 03:43 AM EDT The discovery of the new antibiotic paves the way in the effective treatment for stubborn bacteria that are resistant to the common dosage of present antibiotics. The new drug is from microbes in soil from Italy when soil samples came in for examination. The discovery of this pathogen eliminates a wide range of drug-resistant bacteria during trials and cures infections in lab mice. Researchers from Rutgers University in New Brunswick calls the new antibiotic "Pseuduoridimycin". The data published in the journal Cell last June 15, 2017, show the new drug's mechanism and its course of application. The current drug inhibiting the RNA polymerase is known as Rifampin. The new antibiotic pseuduoridimycin is introduced to inhibit the enzyme RNA polymerase but on a different binding site and mechanism from rifampin resulting no cross-resistance with the previous inhibitor. The co-administration of the new antibiotic by rifampin has a spontaneous rate of only one tenth than that of rifampin alone, reports Phys.org. The new antibiotic acts as a nucleoside analog that hinders chemical reaction with the RNA polymerase enzyme. It functions like the nucleoside triphosphate (NTP), the substance that synthesizes RNA. Pseuduoridimycin binds steadfast with the NTP site on the RNA polymerase, displacing the NTP and inhibiting it from binding. It is the first nucleoside analog inhibitor that prevents bacterial RNA polymerase but not in Human RNA polymerase, reports Science Daily. Board of Governors Professor of Chemistry and Chemical Biology and Laboratory Director, Richard H. Ebright of Waksman Institute of Microbiology at Rutgers University in New Brunswick leads the research of the new antibiotic. He says most researchers think that it is impossible for the new antibiotic to inhibit the Bacteria RNA polymerase enzyme since the NTP binding sites have similar structures and sequences with that of the Human polymerase. Data shows that the new antibiotic has a feature that binds sturdily to bacterial polymerases than that of the human RNA polymerase, Ebright says. It reacts to the structures and sequences of the binding site altering the functions but maintains polymerase activity and bacterial viability. These alterations of the NTP binding sites also disturbs polymerase activity killing the drug-resistant bacteria. The anti-AIDS Drug Inhibitors like Zidovudine, Viread, Lamivudine, Zalcitabine, and Videx are nucleoside analog inhibitors that made an impact on AIDS Disease treatment says CEO of Naicons Srl, Stefano Donaldo. The discovery of the new antibiotic emphasizes the fact that new drugs from nature are effective in creating new antibiotics.